COMMENCER: COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Participants must meet the following criteria on screening examination to be eligible to participate in the study:

• Participants must have histologically confirmed stage I, II, or III colon or rectal adenocarcinoma and have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago.

• Age 18 years or older.

• This study will only include adult participants because colorectal carcinogenesis in children is more likely to be related to a cancer predisposition syndrome with distinct biological mechanisms compared with sporadic colorectal cancer in adults.

• The effects of coffee on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• Subjects must be able and willing to follow study procedures and instructions.

• Ability to understand and the willingness to sign a written informed consent document.

Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Mingyang Song, MD, ScD
msong2@mgh.harvard.edu
(617) 643-3364
Backup
Aparna R Parikh, MD, MS
APARNA.PARIKH@MGH.HARVARD.EDU
(617) 726-4000
Time Frame
Start Date: 2024-03-21
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 80
Treatments
Active_comparator: Coffee
Participants in the active arm will take 15 capsules of coffee, each of which will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend (equivalent daily dose: three cups of coffee). Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
Placebo_comparator: Placebo
Participants in the placebo arm will take 15 capsules of placebo. Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances. Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov